On March 20, in line with the KIMES 2025 schedule, HIGHER CORPORATION held an exclusive launch event introducing its next-generation hyaluronic acid solution, HILO WAVE, to Japanese medical aesthetic physicians. The event began with a product presentation and clinical hands-on session at Min&Min Clinic in Seoul, followed by a networking party at Bunker616 in Gangnam, drawing significant attention from Korean and Japanese professionals.
The event opened with a welcome speech by Dr. Arim Min of Min&Min Clinic. Her fluent Japanese helped set a warm tone, easing the atmosphere for the visiting guests. She also shared insights into successful clinic marketing strategies tailored to Japanese patient preferences, further engaging the attendees.
Dr. Inyong Kim, CEO of HIGHER CORPORATION of SWITZ Dermatology, stated, "HILO WAVE is neither a traditional filler nor a skin booster—it's the most advanced form of hyaluronic acid-based biostimulator." He emphasized the product's distinct position and focus on enhancing overall skin quality beyond mere volume restoration.
The main lecture was delivered by Dr. Hosung Choi of Piena Clinic, with interpretation provided by Dr. Asung Kim of Clinic K in Japan, enhancing the clarity and effectiveness of the presentation for the Japanese audience. Dr. Choi explained that the product's core technology, DHC (Dual Hyaluronic acid Compound), "HILO WAVE uses both high and low molecular weight hyaluronic acid, optimizing outcomes in both the dermis and the fat layer." He added, "In the dermis, it improves skin texture and elasticity, while in the fat layer, it promotes adipocyte regeneration, delivering tailored effects by layer."
Dr. Choi further noted, "It stimulates the production of collagen types 1, 3, 4, and 7 and elastin, improving the skin's overall structure. While type 1 and 3 collagen may contribute to scar formation, type 4 and 7 encourage healthy skin remodeling." He stressed that these benefits arise from natural physiological responses, not inflammatory reactions—one of HILO WAVE's greatest strengths.
Regarding treatment techniques, Dr. Choi explained, "For younger patients, the PDIT technique—injecting 2cc into 10 points—is recommended. For middle-aged and older patients, a cannula-based lifting technique is effective." He emphasized that thanks to HILO WAVE's long-lasting properties, procedures spaced 2–3 months apart still yield sustained results, especially for natural contouring along the outer facial zones.
Four patients were treated using PDIT and cannula techniques during the hands-on session. Participants gained practical insights into the product's application and ease of use. The straightforward and intuitive procedure received positive feedback from physicians, who expressed confidence in its clinical adaptability and potential integration into daily practice.
The event concluded with a networking party at Bunker616, where Japanese doctors and leading Korean KOLs connected in an engaging and well-branded atmosphere. Every detail—from the photo zone to catering—reflected HILO WAVE's brand identity, offering guests a memorable and immersive experience.
This launch event successfully showcased HILO WAVE's clinical strengths and branding excellence. HIGHER CORPORATION is now poised to accelerate its global expansion, focusing on the Japanese market and positioning HILO WAVE as a leading biostimulatory innovation in medical aesthetics.
